CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 217 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Bimekizumab injections every four weeks (Q4W)AI-extracted
Key inclusion· 3
  • ✓Completion of all dosing requirements in feeder study PS0010 without meeting withdrawal criteria
  • ✓Negative interferon gamma release assay (IGRA) at Week 8 of feeder study PS0010
  • ✓Informed consent provided
Key exclusion· 3
  • ✕Prior participation in this extension study
  • ✕Plan to become pregnant (female) or plan partner pregnancy (male) during study or within 20 weeks after last dose
  • ✕Any medical or psychiatric condition that would compromise ability to participate in study

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03010527
NCT03010527Phase 2Completed
CompareCT.gov

A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

UCB Biopharma SRL·interventional·Posted Jan 5, 2017·Updated Oct 18, 2022

In Brief

A Phase 2 clinical trial evaluating Bimekizumab and Placebo for Chronic Plaque Psoriasis. Completed, enrolled 217 participants across 36 sites in 6 countries.

Detailed Summary

This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesCanada, Czechia, Hungary, Japan, Poland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 5, 2017
Enrollment StartDec 14, 2016
Primary CompletionSep 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.5 years ago

Interventions

Bimekizumabdrug

Subjects will receive bimekizumab injections every four weeks (Q4W)

Placeboother

Subjects will receive Placebo injections every four weeks (Q4W)